Although the clinical trial data on current CFTR potentiators has yet to lead to clinical use of these agents in COPD, the data to date confirm the concept that targeting CFTR Cl− ion channel function has the potential to produce meaningful improvements in patients with COPD. This evidence concerns the gene CFTR and chronic obstructive pulmonary disease.